APA (7th ed.) Citation

Deschanvres, C., Reynes, J., Lamaury, I., Rey, D., Palich, R., Bani-Sadr, F., . . . Group, D. S. (2022). Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: Risk of virological failure in a real-life setting. Journal of Antimicrobial Chemotherapy (JAC), 77(1), 196. https://doi.org/10.1093/jac/dkab367

Chicago Style (17th ed.) Citation

Deschanvres, Colin, et al. "Dolutegravir-based Dual Maintenance Regimens Combined with Lamivudine/emtricitabine or Rilpivirine: Risk of Virological Failure in a Real-life Setting." Journal of Antimicrobial Chemotherapy (JAC) 77, no. 1 (2022): 196. https://doi.org/10.1093/jac/dkab367.

MLA (9th ed.) Citation

Deschanvres, Colin, et al. "Dolutegravir-based Dual Maintenance Regimens Combined with Lamivudine/emtricitabine or Rilpivirine: Risk of Virological Failure in a Real-life Setting." Journal of Antimicrobial Chemotherapy (JAC), vol. 77, no. 1, 2022, p. 196, https://doi.org/10.1093/jac/dkab367.